Bayer's eye drug Eylea approved in Europe

Overview Eylea for the Treatment of Wet Age-Related Macular Degeneration

Source: PMLiVE

Bayer's eye drug Eylea approved in Europe

Will compete with Novartis' Lucentis in wet AMD

The European Commission has approved Bayer's Eylea (aflibercept) to treat neovascular wet age-related macular degeneration (AMD), the leading cause of acquired blindness.

Bayer has blockbuster ambitions for the drug, whose sales are predicted to eventually exceed $1.1bn, and this new approval sets Eylea up to compete with Novartis' Lucentis (ranibizumab) in wet AMD in Europe.

One of Eylea's key selling points will be its less frequent dosing. Bayer’s drug is given every two months after three initial monthly injections, compared to monthly Lucentis injections.

Bayer is also likely to compete on drug pricing, following a similar strategy in the US. Eylea was approved by the FDA last year, and was launched and marketed by Bayer's development partner Regeneron at a modest discount to Lucentis.

Full article:
www.pmlive.com/pharma_news/bayers_eye_drug_eylea_approved_in_europe_452213

Eylea (VEGF Trap-Eye) for the Treatment of Wet Age-Related Macular Degeneration

News Age-Related Macular Degeneration